UA72550C2 - Use of retigabin for treatment of neuropathic pain - Google Patents

Use of retigabin for treatment of neuropathic pain Download PDF

Info

Publication number: UA72550C2
Authority: UA; Ukraine
Prior art keywords: pain; treatment; neuropathic pain; hyperalgesia; retigabine
Prior art date: 1999-09-27

Application number

UA2002043557A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Viatris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-27

Filing date

2000-09-22

Publication date

2005-03-15

2000-09-22 Application filed by Viatris Gmbh filed Critical Viatris Gmbh

2005-03-15 Publication of UA72550C2 publication Critical patent/UA72550C2/uk

Links

208000004296 neuralgia Diseases 0.000 title claims abstract description 29
208000021722 neuropathic pain Diseases 0.000 title claims abstract description 28
238000011282 treatment Methods 0.000 title claims abstract description 21
PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 title abstract description 19
150000001875 compounds Chemical class 0.000 claims abstract description 8
150000003839 salts Chemical class 0.000 claims abstract description 3
208000002193 Pain Diseases 0.000 claims description 46
230000036407 pain Effects 0.000 claims description 42
208000004454 Hyperalgesia Diseases 0.000 claims description 35
208000035154 Hyperesthesia Diseases 0.000 claims description 27
206010053552 allodynia Diseases 0.000 claims description 9
208000004983 Phantom Limb Diseases 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 3
208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
238000011321 prophylaxis Methods 0.000 abstract 1
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 22
229960003312 retigabine Drugs 0.000 description 16
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
201000010099 disease Diseases 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 12
229960002870 gabapentin Drugs 0.000 description 11
210000002569 neuron Anatomy 0.000 description 11
230000006835 compression Effects 0.000 description 10
238000007906 compression Methods 0.000 description 10
230000000694 effects Effects 0.000 description 10
210000005036 nerve Anatomy 0.000 description 9
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000000202 analgesic effect Effects 0.000 description 7
238000000034 method Methods 0.000 description 7
230000008058 pain sensation Effects 0.000 description 7
210000000278 spinal cord Anatomy 0.000 description 7
230000001684 chronic effect Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
241000700159 Rattus Species 0.000 description 5
238000002266 amputation Methods 0.000 description 5
229940035676 analgesics Drugs 0.000 description 5
239000000730 antalgic agent Substances 0.000 description 5
230000001773 anti-convulsant effect Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
210000003414 extremity Anatomy 0.000 description 5
230000035807 sensation Effects 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
208000028389 Nerve injury Diseases 0.000 description 4
206010056238 Phantom pain Diseases 0.000 description 4
239000001961 anticonvulsive agent Substances 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
229940005513 antidepressants Drugs 0.000 description 4
229960000623 carbamazepine Drugs 0.000 description 4
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
238000002483 medication Methods 0.000 description 4
230000008764 nerve damage Effects 0.000 description 4
210000004126 nerve fiber Anatomy 0.000 description 4
230000008447 perception Effects 0.000 description 4
210000001428 peripheral nervous system Anatomy 0.000 description 4
101100310622 Mus musculus Soga1 gene Proteins 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
239000013543 active substance Substances 0.000 description 3
229960003965 antiepileptics Drugs 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
230000008533 pain sensitivity Effects 0.000 description 3
208000035824 paresthesia Diseases 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000008925 spontaneous activity Effects 0.000 description 3
238000002636 symptomatic treatment Methods 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
206010001497 Agitation Diseases 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000006399 behavior Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
229960003667 flupirtine Drugs 0.000 description 2
230000000917 hyperalgesic effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
206010062198 microangiopathy Diseases 0.000 description 2
230000008760 nerve sprouting Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000000324 neuroprotective effect Effects 0.000 description 2
210000000929 nociceptor Anatomy 0.000 description 2
229940005483 opioid analgesics Drugs 0.000 description 2
230000037324 pain perception Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
210000002820 sympathetic nervous system Anatomy 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
235000011293 Brassica napus Nutrition 0.000 description 1
240000008100 Brassica rapa Species 0.000 description 1
235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
206010013142 Disinhibition Diseases 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
206010021403 Illusion Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
208000001294 Nociceptive Pain Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
208000003728 Vulvodynia Diseases 0.000 description 1
206010069055 Vulvovaginal pain Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000024330 bloating Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
230000009956 central mechanism Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
238000002224 dissection Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000773 effect on pain Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
229940121367 non-opioid analgesics Drugs 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000026416 response to pain Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
210000001032 spinal nerve Anatomy 0.000 description 1
210000000273 spinal nerve root Anatomy 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
229960004394 topiramate Drugs 0.000 description 1
238000012549 training Methods 0.000 description 1
229960004380 tramadol Drugs 0.000 description 1
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
230000007704 transition Effects 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1
229940102566 valproate Drugs 0.000 description 1
230000001790 virustatic effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
-1 vitamin VI Natural products 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA2002043557A 1999-09-27 2000-09-22 Use of retigabin for treatment of neuropathic pain UA72550C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/406,135 US6117900A (en)	1999-09-27	1999-09-27	Use of retigabine for the treatment of neuropathic pain
PCT/EP2000/009284 WO2001022953A2 (de)	1999-09-27	2000-09-22	Verwendung von retigabin zur behandlung von neuropathischen schmerzen

Publications (1)

Publication Number	Publication Date
UA72550C2 true UA72550C2 (en)	2005-03-15

Family

ID=23606675

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002043557A UA72550C2 (en)	1999-09-27	2000-09-22	Use of retigabin for treatment of neuropathic pain

Country Status (35)

Country	Link
US (1)	US6117900A (cs)
EP (1)	EP1223927B1 (cs)
JP (1)	JP2003510273A (cs)
KR (1)	KR100730829B1 (cs)
CN (2)	CN101444498A (cs)
AR (1)	AR026163A1 (cs)
AT (1)	ATE288748T1 (cs)
AU (1)	AU777764B2 (cs)
BG (1)	BG65795B1 (cs)
BR (1)	BR0014293A (cs)
CA (2)	CA2384504C (cs)
CZ (1)	CZ295980B6 (cs)
DE (1)	DE50009504D1 (cs)
DK (1)	DK1223927T3 (cs)
EE (1)	EE05073B1 (cs)
ES (1)	ES2237461T3 (cs)
HK (1)	HK1052471A1 (cs)
HR (1)	HRP20020234A2 (cs)
HU (1)	HUP0202853A3 (cs)
IL (3)	IL148309A0 (cs)
IS (1)	IS6303A (cs)
MX (1)	MXPA02003179A (cs)
NO (1)	NO329744B1 (cs)
NZ (1)	NZ517616A (cs)
PL (1)	PL200847B1 (cs)
PT (1)	PT1223927E (cs)
RS (1)	RS50091B (cs)
RU (1)	RU2264813C2 (cs)
SI (1)	SI1223927T1 (cs)
SK (1)	SK286057B6 (cs)
TR (1)	TR200200706T2 (cs)
TW (1)	TWI257304B (cs)
UA (1)	UA72550C2 (cs)
WO (1)	WO2001022953A2 (cs)
ZA (1)	ZA200202449B (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001093852A2 (en) *	2000-06-09	2001-12-13	The Regents Of The University Of California	Method of treating pain using nalbuphine and opioid antagonists
US6348486B1 (en)	2000-10-17	2002-02-19	American Home Products Corporation	Methods for modulating bladder function
US6589986B2 (en) *	2000-12-20	2003-07-08	Wyeth	Methods of treating anxiety disorders
WO2002061075A1 (fr) *	2001-02-01	2002-08-08	Takeda Chemical Industries, Ltd.	Proteine de recepteur couple aux proteines g et adn correspondant
CA2438868A1 (en)	2001-02-20	2002-09-19	Valentin K. Gribkoff	Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US20020183395A1 (en) *	2001-04-04	2002-12-05	Wyeth	Methods for treating hyperactive gastric motility
EP1545535A4 (en) *	2002-09-05	2008-06-04	Scios Inc	TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE
US20080039461A1 (en) *	2002-09-05	2008-02-14	Protter Andrew A	Treatment of pain by inhibition of p38 map kinase
US7632866B2 (en) *	2002-10-21	2009-12-15	Ramot At Tel Aviv University	Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2004054511A2 (en) *	2002-12-13	2004-07-01	The Regents Of The University Of California	Analgesic combination comprising nalbuphine
CN100448867C (zh) *	2002-12-27	2009-01-07	H·隆德贝克有限公司	用于治疗中枢神经系统疾病的1,2,4-三氨基苯衍生物
ES2282701T3 (es) *	2002-12-27	2007-10-16	H. Lundbeck A/S	Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central.
MXPA05010174A (es) *	2003-04-25	2005-11-08	Lundbeck & Co As H	Derivados de indol e indolina sustituidos.
US20050089559A1 (en) *	2003-10-23	2005-04-28	Istvan Szelenyi	Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en)	2004-03-12	2011-10-01	Lundbeck & Co As H	Substituted morpholine and thiomorpholine derivatives
EP1861394A1 (en)	2005-03-03	2007-12-05	H.Lundbeck A/S	Substituted pyridine derivatives
US7960436B2 (en) *	2006-06-05	2011-06-14	Valeant Pharmaceuticals International	Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) *	2006-08-18	2008-02-21	Valeant Pharmaceuticals North America	Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) *	2006-08-23	2015-03-31	Valeant Pharmaceuticals International	N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
SG174095A1 (en) *	2006-08-23	2011-09-29	Valeant Pharmaceuticals Int	Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) *	2006-10-10	2014-05-13	Valeant Pharmaceuticals International	N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) *	2006-11-28	2009-11-11	威朗国际制药公司	作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
US8367684B2 (en) *	2007-06-13	2013-02-05	Valeant Pharmaceuticals International	Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) *	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) *	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CN101868443A (zh) *	2007-09-20	2010-10-20	特拉维夫大学拉莫特有限公司	N-苯基邻氨基苯甲酸衍生物及其用途
US20100323015A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
US20100323016A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
AU2009270768A1 (en) *	2008-07-18	2010-01-21	Valeant Pharmaceuticals International	Modified release formulation and methods of use
DE102009013613A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Trockenverarbeitung von Retigabin
DE102009013611A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
IT1398282B1 (it) *	2009-07-30	2013-02-22	Difass S A Ora Farmapros S P A	Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) *	2009-10-06	2011-04-14	Johnson Controls Technology Company	Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) *	2010-03-31	2011-09-21	Mustafa Nevzat �La� Sanay�� A.�.	Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) *	2011-03-31	2012-04-10	Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России"	Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) *	2011-12-23	2013-07-24	山东创新药物研发有限公司	瑞替加滨的晶型d及其制备方法
US9345689B2 (en) *	2012-05-18	2016-05-24	Gruenenthal Gmbh	Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en)	2012-05-18	2016-04-26	Gruenenthal Gmbh	Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en)	2012-05-18	2013-11-21	Gruenenthal Gmbh	Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
CN103271899A (zh) *	2012-12-30	2013-09-04	北京阜康仁生物制药科技有限公司	瑞替加滨粉碎粒度在制剂中的应用
CN106176715A (zh) *	2016-06-29	2016-12-07	青岛云天生物技术有限公司	一种神经病理性疼痛治疗用药物组合物及其用途
CN105919990A (zh) *	2016-06-29	2016-09-07	青岛云天生物技术有限公司	用于预防和治疗神经病理性疼痛的药物组合物及其用途
WO2019014547A1 (en)	2017-07-14	2019-01-17	Texas Tech University System	FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
IL273893B2 (en)	2017-10-09	2025-11-01	Univ Ramot	Modulators of potassium ion and trpv1 channels and uses thereof
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
MX2022005490A (es)	2019-11-08	2022-08-10	Xenon Pharmaceuticals Inc	Metodos para el tratamiento de trastornos depresivos.
US11957675B2 (en)	2021-02-09	2024-04-16	Xenon Pharmaceuticals Inc.	Methods and uses for treating anhedonia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4200259A1 (de) *	1992-01-08	1993-07-15	Asta Medica Ag	Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) *	1995-10-26	1997-04-30	Asta Medica Ag	Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) *	1999-07-01	1999-09-01	Glaxo Group Ltd	Medical use

1999
- 1999-09-27 US US09/406,135 patent/US6117900A/en not_active Expired - Lifetime
2000
- 2000-09-21 TW TW089119495A patent/TWI257304B/zh not_active IP Right Cessation
- 2000-09-22 SI SI200030641T patent/SI1223927T1/xx unknown
- 2000-09-22 AU AU79061/00A patent/AU777764B2/en not_active Ceased
- 2000-09-22 CN CNA2008101752753A patent/CN101444498A/zh active Pending
- 2000-09-22 WO PCT/EP2000/009284 patent/WO2001022953A2/de not_active Ceased
- 2000-09-22 AT AT00969283T patent/ATE288748T1/de active
- 2000-09-22 SK SK292-2002A patent/SK286057B6/sk not_active IP Right Cessation
- 2000-09-22 HR HR20020234A patent/HRP20020234A2/hr not_active Application Discontinuation
- 2000-09-22 PT PT00969283T patent/PT1223927E/pt unknown
- 2000-09-22 RU RU2002109240/15A patent/RU2264813C2/ru not_active IP Right Cessation
- 2000-09-22 BR BR0014293-0A patent/BR0014293A/pt not_active Application Discontinuation
- 2000-09-22 UA UA2002043557A patent/UA72550C2/uk unknown
- 2000-09-22 KR KR1020027003903A patent/KR100730829B1/ko not_active Expired - Fee Related
- 2000-09-22 EP EP00969283A patent/EP1223927B1/de not_active Expired - Lifetime
- 2000-09-22 HK HK03104879.5A patent/HK1052471A1/zh unknown
- 2000-09-22 TR TR2002/00706T patent/TR200200706T2/xx unknown
- 2000-09-22 CZ CZ2002989A patent/CZ295980B6/cs not_active IP Right Cessation
- 2000-09-22 RS YUP-203/02A patent/RS50091B/sr unknown
- 2000-09-22 PL PL353393A patent/PL200847B1/pl not_active IP Right Cessation
- 2000-09-22 HU HU0202853A patent/HUP0202853A3/hu unknown
- 2000-09-22 DE DE50009504T patent/DE50009504D1/de not_active Expired - Lifetime
- 2000-09-22 IL IL14830900A patent/IL148309A0/xx active IP Right Grant
- 2000-09-22 EE EEP200200145A patent/EE05073B1/xx not_active IP Right Cessation
- 2000-09-22 MX MXPA02003179A patent/MXPA02003179A/es active IP Right Grant
- 2000-09-22 CA CA002384504A patent/CA2384504C/en not_active Expired - Fee Related
- 2000-09-22 CN CNB008133042A patent/CN100522155C/zh not_active Expired - Fee Related
- 2000-09-22 NZ NZ517616A patent/NZ517616A/xx not_active IP Right Cessation
- 2000-09-22 JP JP2001526165A patent/JP2003510273A/ja not_active Ceased
- 2000-09-22 CA CA002659048A patent/CA2659048A1/en not_active Abandoned
- 2000-09-22 ES ES00969283T patent/ES2237461T3/es not_active Expired - Lifetime
- 2000-09-22 DK DK00969283T patent/DK1223927T3/da active
- 2000-09-26 AR ARP000105028A patent/AR026163A1/es unknown
2002
- 2002-02-21 IL IL148309A patent/IL148309A/en not_active IP Right Cessation
- 2002-02-27 BG BG106450A patent/BG65795B1/bg unknown
- 2002-03-18 IS IS6303A patent/IS6303A/is unknown
- 2002-03-21 NO NO20021418A patent/NO329744B1/no not_active IP Right Cessation
- 2002-03-27 ZA ZA200202449A patent/ZA200202449B/xx unknown
2007
- 2007-10-30 IL IL187030A patent/IL187030A/en active IP Right Grant

Also Published As

Publication number	Publication date
TWI257304B (en)	2006-07-01
CZ295980B6 (cs)	2005-12-14
KR20020042691A (ko)	2002-06-05
EP1223927B1 (de)	2005-02-09
CN101444498A (zh)	2009-06-03
HRP20020234A2 (en)	2003-06-30
EE200200145A (et)	2003-04-15
ES2237461T3 (es)	2005-08-01
CN1409632A (zh)	2003-04-09
NO20021418L (no)	2002-03-21
PL200847B1 (pl)	2009-02-27
AR026163A1 (es)	2003-01-29
BG65795B1 (bg)	2009-12-31
AU7906100A (en)	2001-04-30
CZ2002989A3 (cs)	2002-08-14
US6117900A (en)	2000-09-12
AU777764B2 (en)	2004-10-28
CA2659048A1 (en)	2001-04-05
IL148309A0 (en)	2002-09-12
HK1052471A1 (zh)	2003-09-19
HUP0202853A2 (hu)	2002-12-28
IL187030A0 (en)	2008-02-09
PL353393A1 (en)	2003-11-17
SI1223927T1 (cs)	2005-08-31
KR100730829B1 (ko)	2007-06-20
NO20021418D0 (no)	2002-03-21
SK2922002A3 (en)	2002-08-06
BG106450A (en)	2002-09-30
NO329744B1 (no)	2010-12-13
TR200200706T2 (tr)	2002-10-21
DK1223927T3 (da)	2005-04-11
IL187030A (en)	2011-06-30
CA2384504A1 (en)	2001-04-05
BR0014293A (pt)	2002-05-21
CN100522155C (zh)	2009-08-05
RU2264813C2 (ru)	2005-11-27
DE50009504D1 (de)	2005-03-17
EP1223927A2 (de)	2002-07-24
WO2001022953A3 (de)	2002-05-23
EE05073B1 (et)	2008-10-15
RS50091B (sr)	2009-01-22
NZ517616A (en)	2002-12-20
WO2001022953A2 (de)	2001-04-05
RU2002109240A (ru)	2004-01-10
JP2003510273A (ja)	2003-03-18
MXPA02003179A (es)	2003-08-20
IL148309A (en)	2007-12-03
ATE288748T1 (de)	2005-02-15
YU20302A (sh)	2005-03-15
PT1223927E (pt)	2005-06-30
ZA200202449B (en)	2003-03-26
IS6303A (is)	2002-03-18
HUP0202853A3 (en)	2003-10-28
SK286057B6 (sk)	2008-02-05
CA2384504C (en)	2009-05-26

Publication	Publication Date	Title
UA72550C2 (en)	2005-03-15	Use of retigabin for treatment of neuropathic pain
EP0491094B1 (en)	1996-09-11	Felbamate for treating Lennox-Gastaut syndrome
JP6137833B2 (ja)	2017-05-31	脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
Yang et al.	2014	Analgesic treatment with pregabalin does not prevent persistent pain after peripheral nerve injury in the rat
DE60128793T2 (de)	2008-02-07	Verfahren und Zusammensetzung zur Behandlung von Neoplasmen
CN117180252B (zh)	2025-05-30	β氨基丙腈在制备逆转拉莫三嗪耐药制剂中的应用
US20020137758A1 (en)	2002-09-26	Composition and method for treatment of cerebral ischemia
CN114028396B (zh)	2023-04-11	汉防己甲素在用于制备治疗纤维肌痛的药物中的应用
KR960006068B1 (ko)	1996-05-08	이미다벤조디아제핀을 함유하는 공포상태의 예방 및 중지용 약제
KR20200026962A (ko)	2020-03-11	염증 반응을 포함하는 통증 상태에서 무통증을 위한 말초 제한된 이중 작용성 카파 및 델타 오피오이드 작용제
CN107998126A (zh)	2018-05-08	青蒿素的应用
CN119700946A (zh)	2025-03-28	Ryk-Fc融合蛋白在制备抗癌性疼痛药物中的应用
Sherif	1998	Influence of vigabatrin on exploratory behaviour in rats upon diazepam withdrawal
Cohen	2010	Current medical therapy
Garg et al.	2007	Treatment of pain, paresthesias and paroxysmal disorders in multiple sclerosis
KESTEN	1927	Treatment of Urticaria with Ephedrine